Form 4: Director Receives Stock Options at 4D Molecular Therapeutics

Glenn Sblendorio, a Director at 4D Molecular Therapeutics, Inc., was granted 50,000 stock options with an exercise price of $9.42.

Summary

• Glenn Sblendorio, a Director at 4D Molecular Therapeutics, Inc. (FDMT), received a grant of 50,000 stock options on June 17, 2026.
• The stock options have an exercise price of $9.42 per share.
• These options are part of the company's non-employee director compensation program.
• The options will vest over a period of three years, with one-third vesting on June 17, 2027, and the remainder vesting in equal monthly installments until fully vested on June 17, 2029, contingent upon continued service.
• A Change in Control event will trigger full vesting of the stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director compensation event rather than a significant financial or strategic development for the company.

Positives

• Director compensation through stock options aligns the interests of management with shareholders.
• The vesting schedule encourages long-term commitment from the director.
• Potential for full vesting upon a Change in Control could incentivize actions beneficial to shareholders in such scenarios.

Negatives

• The value of the stock options is subject to market fluctuations and the company's future performance.
• The exercise price of $9.42 may be higher than the current market price, depending on the stock's trading performance.

Risks

• The value of the granted stock options is contingent on the future stock price of 4D Molecular Therapeutics.
• Continued service is required for vesting, meaning the director could forfeit unvested options if they leave the company before the vesting dates.
• A Change in Control event, while triggering vesting, could also represent a significant change in the company's strategic direction or ownership, which may or may not be beneficial to all stakeholders.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and stock price appreciation, as well as the occurrence of a Change in Control event. The vesting schedule indicates a commitment to the company's long-term success.

Management Comments

• The stock option grant was automatically granted pursuant to the terms of the Company's non-employee director compensation program.
• The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029.
• Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation, especially in companies focused on long-term development and potential M&A activity.

Related Party Transactions

• The grant of 50,000 stock options to Director Glenn Sblendorio is a related party transaction, as it involves compensation to a director.

Stakeholder Impact

• Shareholders: The grant of options dilutes existing share ownership but also aligns director incentives with stock performance.
• Employees: May be impacted by the overall compensation structure and potential future dilution.
• Management: The director's compensation is directly tied to the company's success and stock value.

Next Steps

• Continued service by Glenn Sblendorio to meet vesting requirements.
• Monitoring of the company's stock price performance.
• Potential vesting acceleration upon a Change in Control event.

Key Dates

Keywords

stock options, director compensation, 4D Molecular Therapeutics, FDMT, SEC Form 4, insider trading, equity award, vesting schedule, Change in Control